Prof.

Mustafa ÖZGÜROĞLU


Cerrahpasa Faculty of Medicine

Department of Internal Medicine

Department of Internal Medicine

Education Information

1993 - 1996

1993 - 1996

Post Doctorate of Medicine

İstanbul Üniversitesi, Cerrahpaşa Tıp Fakültesi, Tıbbi Onkoloji, Turkey

1988 - 1993

1988 - 1993

Expertise In Medicine

İstanbul Üniversitesi, Cerrahpaşa Tıp Fakültesi, İç Hastalıkları , Turkey

Foreign Languages

B1 Intermediate

B1 Intermediate

French

C1 Advanced

C1 Advanced

English

Research Areas

Medicine, Health Sciences, Internal Medicine Sciences, Internal Diseases , Oncology

Academic Titles / Tasks

1988 - Continues

1988 - Continues

Professor

Istanbul University, Dahili Bilimler

Articles Published in Journals That Entered SCI, SSCI and AHCI Indexes

2021

2021

Comparison of iodine-125 plaque brachytherapy and gamma knife stereotactic radiosurgery treatment outcomes for uveal melanoma patients.

Guleser U. Y. , Sarici A. M. , Ucar D., Gonen B., Sengul Samanci N., Özgüroğlu M.

Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2021 (Journal Indexed in SCI Expanded) identifier identifier

2021

2021

A Randomized Phase II Study of Anti-CSF-1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple Negative Breast Cancer.

Kuemmel S., Campone M., Loirat D., López López R., Beck J. T. , De Laurentiis M., et al.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2021 (Journal Indexed in SCI Expanded) Sustainable Development identifier

2021

2021

Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial.

Fuchs C. S. , Özgüroğlu M. , Bang Y., Di Bartolomeo M., Mandala M., Ryu M., et al.

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2021 (Journal Indexed in SCI) Creative Commons License identifier identifier identifier

2021

2021

Avelumab vs docetaxel in patients with platinum-treated advanced non-small-cell lung cancer: 2-year follow-up from the JAVELIN Lung 200 phase 3 trial.

Park K., Özgüroğlu M. , Vansteenkiste J., Spigel D., Yang J. C. , Ishii H., et al.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, vol.16, pp.1369-1378, 2021 (Journal Indexed in SCI) Sustainable Development identifier identifier identifier

2021

2021

Reply by Authors.

Agarwal N., McQuarrie K., Bjartell A., Chowdhury S., Pereira de Santana Gomes A. J. , Chung B. H. , et al.

The Journal of urology, 2021 (Journal Indexed in SCI Expanded) identifier

2021

2021

Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study.

Chi K. N. , Chowdhury S., Bjartell A., Chung B. H. , Pereira de Santana Gomes A. J. , Given R., et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol.39, pp.2294-2304, 2021 (Journal Indexed in SCI) identifier identifier identifier

2021

2021

Brief report: Four-year survival with durvalumab after chemoradiotherapy in Stage III NSCLC - an update from the PACIFIC trial.

Faivre-Finn C., Vicente D., Kurata T., Planchard D., Paz-Ares L., Vansteenkiste J. F. , et al.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, vol.16, pp.860-867, 2021 (Journal Indexed in SCI) identifier identifier identifier

2020

2020

Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer.

Hussain M., Mateo J., Fizazi K., Saad F., Shore N., Sandhu S., et al.

The New England journal of medicine, vol.383, pp.2345-2357, 2020 (Journal Indexed in SCI) Sustainable Development identifier identifier identifier

2020

2020

Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC.

Herbst R., Giaccone G., de M., Reinmuth N., Vergnenegre A., Barrios C., et al.

The New England journal of medicine, vol.383, pp.1328-1339, 2020 (Journal Indexed in SCI) Sustainable Development identifier identifier identifier

2019

2019

Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer.

CHI K., AGARWAL N., BJARTELL A., CHUNG B., PEREIRA D. S. G. A. , GIVEN R., et al.

The New England journal of medicine, vol.381, pp.13-24, 2019 (Journal Indexed in SCI) Sustainable Development identifier identifier identifier

2018

2018

Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC.

ANTONIA S., VILLEGAS A., DANIEL D., VICENTE D., MURAKAMI S., HUI R., et al.

The New England journal of medicine, vol.379, pp.2342-2350, 2018 (Journal Indexed in SCI) Creative Commons License identifier identifier identifier

2018

2018

Effect of Induction Chemotherapy in the PACIFIC Study

Spigel D., Vansteenkiste J., Reck M., Wakelee H., Ozguroglu M. , Daniel D., et al.

JOURNAL OF THORACIC ONCOLOGY, vol.13, no.10, 2018 (Journal Indexed in SCI) Creative Commons License identifier

2018

2018

Expanded Efficacy and Safety Analysis of PACIFIC Based on a PD-L1 Cutpoint of 25%

Spira A., Planchard D., Cho B. C. , Ozguroglu M. , Daniel D., Villegas A., et al.

JOURNAL OF THORACIC ONCOLOGY, vol.13, no.10, 2018 (Journal Indexed in SCI) Creative Commons License identifier

2018

2018

Outcomes of Patients < 70 or >= 70 Years of Age in PACIFIC

Socinski M., Ozguroglu M. , Villegas A., Daniel D., Vicente D., Murakami S., et al.

JOURNAL OF THORACIC ONCOLOGY, vol.13, no.10, 2018 (Journal Indexed in SCI) Creative Commons License identifier

2018

2018

Durvalumab in Stage III Non-Small-Cell Lung Cancer REPLY

Antonia S. J. , Ozguroglu M.

NEW ENGLAND JOURNAL OF MEDICINE, vol.378, no.9, pp.869-870, 2018 (Journal Indexed in SCI) Sustainable Development identifier

2018

2018

Durvalumab in Stage III Non-Small-Cell Lung Cancer.

Antonia S., Özgüroğlu M.

The New England journal of medicine, vol.378, pp.869-870, 2018 (Journal Indexed in SCI) Sustainable Development identifier identifier

2017

2017

Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer

Antonia S. J. , Villegas A., Daniel D., Vicente D., Murakami S., Hui R., et al.

NEW ENGLAND JOURNAL OF MEDICINE, vol.377, no.20, pp.1919-1929, 2017 (Journal Indexed in SCI) Creative Commons License Sustainable Development identifier identifier identifier

2017

2017

Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer

Fizazi K., NamPhuong Tran N. T. , Fein L., Matsubara N., Rodriguez-Antolin A., Alekseev B. Y. , et al.

NEW ENGLAND JOURNAL OF MEDICINE, vol.377, no.4, pp.352-360, 2017 (Journal Indexed in SCI) Sustainable Development identifier identifier identifier

2015

2015

Is perineural invasion (PN) a determinant of disease free survival in early stage colorectal cancer?

Ozturk M. A. , DANE F., Karagoz S., Tural D., Selcukbiricik F., Demirelli F., et al.

Hepato-Gastroenterology, vol.62, no.137, pp.59-64, 2015 (Journal Indexed in SCI Expanded) identifier identifier identifier

2014

2014

Receptor expression discrepancy between primary and metastatic breast cancer lesions

Ozen D. S. K. , Öztürk M. S. , Aydin O. , Turna Z. H. , Ilvan Ş. , Ozguroglu M.

Oncology Research and Treatment, vol.37, no.11, pp.622-626, 2014 (Journal Indexed in SCI Expanded) Sustainable Development identifier identifier identifier

2013

2013

Dendritic cell sarcoma: A pooled analysis including 462 cases with presentation of our case series

Saygin C., Uzunaslan D., Ozguroglu M. , Senocak M. , Tuzuner N.

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, vol.88, no.2, pp.253-271, 2013 (Journal Indexed in SCI) identifier identifier identifier

2013

2013

Patterns of complementary and alternative medicine use among turkish cancer patients

Yildiz I., Ozguroglu M. , TOPTAŞ T., Turna H. , Sen F., Yildiz M.

Journal of Palliative Medicine, vol.16, no.4, pp.383-390, 2013 (Journal Indexed in SCI Expanded) Sustainable Development identifier identifier identifier

2013

2013

Primary osteosarcoma of the heart: Experience of an unusual case

Özen D. S. K. , Öztürk M. A. , Selcukbiricik F., Esatoglu S. N. , Turna Z. H. , Beyaz P., et al.

Case Reports in Oncology, vol.6, no.1, pp.224-228, 2013 (Journal Indexed in SCI Expanded) identifier identifier

2013

2013

Clinicopathological Features and Localization of Gastric Cancers and their Effects on Survival in Turkey

SELÇUKBİRİCİK F., Tural D., Bilici A. , Uzel E. K. , Ozguroglu M. , Demirelli F. , et al.

ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, vol.14, no.1, pp.553-556, 2013 (Journal Indexed in SCI) Creative Commons License Sustainable Development identifier identifier identifier

2012

2012

Prognostic factors for survival in the phase III TROPIC trial.

Sartor A. O. , Oudard S., Ozguroglu M. , Hansen S., Machiels J. H. , Kocak I., et al.

JOURNAL OF CLINICAL ONCOLOGY, vol.30, no.5, 2012 (Journal Indexed in SCI) identifier

2010

2010

Gastroenteropancreatic Neuroendocrine tumors: 10-Year experience in a single center

Yildiz O., Ozguroglu M. , Yanmaz T., Turna H. , Serdengecti S., Dogusoy G.

Medical Oncology, vol.27, no.4, pp.1050-1056, 2010 (Journal Indexed in SCI Expanded) identifier identifier identifier

2010

2010

Surgery for isolated liver metastasis of ovarian cancer

Pekmezci S., Saribeyoglu K., Aytac E., Arvas M., Demirkiran F. , Ozguroglu M.

Asian Journal of Surgery, vol.33, no.2, pp.83-88, 2010 (Journal Indexed in SCI Expanded) Sustainable Development identifier identifier identifier

2008

2008

Metastasis from breast carcinoma to endometrial polyp

Aydin O. , Bagci P., Akyildiz E. U. , Ozguroglu M. , Ilvan Ş.

European Journal of Gynaecological Oncology, vol.29, no.6, pp.666-668, 2008 (Journal Indexed in SCI Expanded) identifier identifier identifier

2008

2008

Determining predominating histologic component in malignant mixed müllerian tumors: Is it worth it?

Ozguroglu M. , Bilici A., Ilvan Ş. , Turna H. , Atalay B., Mandel N., et al.

International Journal of Gynecological Cancer, vol.18, no.4, pp.809-812, 2008 (Journal Indexed in SCI Expanded) identifier identifier identifier

2007

2007

A case-control study of non-alcoholic fatty liver disease in breast cancer

Bilici A. , Ozguroglu M. , Mihmanh I., Turna H. , Adaletli I.

Medical Oncology, vol.24, no.4, pp.367-371, 2007 (Journal Indexed in SCI Expanded) Sustainable Development identifier identifier identifier

2007

2007

Neuroblastoma in adults, presentation of 2 cases

Demir H., Aydin O. , Durak H. , Dervisoglu S. , Ozguroglu M. , Sahinler I.

VIRCHOWS ARCHIV, vol.451, no.2, pp.577, 2007 (Journal Indexed in SCI) identifier

2007

2007

Paraneoplastic pemphigus associated with fludarabine use

Yıldız O. , Özgüroğlu M. , Yanmaz M. R. , Turna H. , Kursunoglu S. G. , Antonov M., et al.

Medical Oncology, vol.24, no.1, pp.115-118, 2007 (Journal Indexed in SCI Expanded) identifier identifier identifier

2007

2007

Thymoma with chronic diarrhea: Report of two cases and review of the literature

Yildiz O. , Ozguroglu M. , TURNA H. , YANMAZ T., Kaynak K. , Akman C. , et al.

Medical Oncology, vol.24, no.1, pp.119-123, 2007 (Journal Indexed in SCI Expanded) Sustainable Development identifier identifier identifier

2007

2007

The role of US and MR imaging in detecting local chest wall tumor recurrence after mastectomy

Yilmaz M. H. , Esen G., Ayarcan Y., Aydogan F., Ozguroglu M. , Demir G., et al.

DIAGNOSTIC AND INTERVENTIONAL RADIOLOGY, vol.13, no.1, pp.13-18, 2007 (Journal Indexed in SCI) identifier identifier identifier

2007

2007

C-reactive protein as an acute phase protein in cancer patients

Bolayirli M. , Turna H. , ORHANOĞLU T., Ozaras R., İLHAN M., Ozguroglu M.

Medical Oncology, vol.24, no.3, pp.338-344, 2007 (Journal Indexed in SCI Expanded) identifier identifier identifier

2006

2006

Megestrol acetate induced hypoadrenalism with cushingoid phenotype in endometrial cancer [1]

Ozguroglu M. , Yildiz O., Turna H. , Kadioglu P.

Gynecologic Oncology, vol.101, no.1, pp.183, 2006 (Journal Indexed in SCI Expanded) identifier identifier identifier

2006

2006

Small cell carcinoma of the bladder: A case report and review of the literature

Tunc B. , Ozguroglu M. , Demirkesen O. , Alan C., Durak H. , Dincbas F. O. , et al.

International Urology and Nephrology, vol.38, no.1, pp.15-19, 2006 (Journal Indexed in SCI Expanded) identifier identifier identifier

2006

2006

Devastating effects of chemotherapy: Deafness and acute renal failure in a patient with epithelial ovarian cancer

Ozguroglu M. , Sari O., Turna H.

International Journal of Gynecological Cancer, vol.16, pp.394-396, 2006 (Journal Indexed in SCI Expanded) Sustainable Development identifier identifier identifier

2006

2006

Adult paratesticular myxofibrosarcoma: report of a rare entity and review of the literature.

OZKAN B., OZGÜROĞLU M. , Ozkara H. , DURAK H. , TALAT Z.

International urology and nephrology, vol.38, pp.5-7, 2006 (Journal Indexed in SCI) identifier identifier identifier

2005

2005

Delayed onset bleomycin-induced pneumonitis

Uzel I., Ozguroglu M. , Uzel B., Kaynak K., Demirhan O., Akman C., et al.

UROLOGY, vol.66, no.1, 2005 (Journal Indexed in SCI) Sustainable Development identifier identifier identifier

2005

2005

Does the incidence of anal canal cancers differ in Moslem societies?

Yumuk P., Abacioglu U., Demir G., Cabuk D., Dane F., Gumus M., et al.

INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, vol.20, no.1, pp.76, 2005 (Journal Indexed in SCI) Sustainable Development identifier identifier identifier

2004

2004

Rituximab-induced tumor progression: Does it really happen?

Ozguroglu M. , Turna H.

Medical Oncology, vol.21, no.2, pp.205-206, 2004 (Journal Indexed in SCI Expanded) identifier identifier identifier

2004

2004

Reactivation of hepatitis B virus infection with cytotoxic therapy in non-Hodgkin's lymphoma

Ozguroglu M. , Bilici A., Turna H. , Serdengecti S.

Medical Oncology, vol.21, no.1, pp.67-72, 2004 (Journal Indexed in SCI Expanded) identifier identifier identifier

2004

2004

Do we really benefit from checking tumor markers in detecting recurrence in gastrointestinal cancer?

Ozguroglu M. , Turna H.

Journal of B.U.ON., vol.9, no.2, pp.179-182, 2004 (Journal Indexed in SCI Expanded) identifier identifier

2004

2004

Should mammographic screening be done in primary ovarian cancer? A case control study in Turkish women

Ozguroglu M. , Avci B., Turna H. , Esen G., Arun B., Celik V. , et al.

Medical Oncology, vol.21, no.2, pp.139-143, 2004 (Journal Indexed in SCI Expanded) identifier identifier identifier

2004

2004

Multiple primary tumors in cancer patients in a Turkish population

Ozguroglu M. , Donmez H., Turna H. , Mandel N.

ANNALS OF ONCOLOGY, vol.15, pp.149, 2004 (Journal Indexed in SCI) identifier

2003

2003

Intrathoracic extravasation of antineoplastic agents - Case report and systematic review

Bozkurt A., Uzel B., Akman C., Ozguroglu M. , Mandel N.

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, vol.26, no.2, pp.121-123, 2003 (Journal Indexed in SCI) identifier identifier identifier

2002

2002

Simultaneous presentation of hepatocellular carcinoma in identical twin brothers

Demir G., Belentepe S., Ozguroglu M. , Celik A., Sayhan N., Tekin S., et al.

MEDICAL ONCOLOGY, vol.19, no.2, pp.113-116, 2002 (Journal Indexed in SCI) identifier identifier identifier

2002

2002

Flutamide-induced acute renal failure in a patient with metastatic prostate cancer.

Altiparmak M. R. , Bilici A., Kisacik B., Ozguroglu M.

Medical oncology (Northwood, London, England), vol.19, no.2, pp.117-9, 2002 (Journal Indexed in SCI Expanded) Sustainable Development identifier identifier identifier

2001

2001

Metastatic cardiac myxoma

KAYNAK K. , BESIRLI K., ARSLAN C., OZGUROGLU M. , Oz B.

ANNALS OF THORACIC SURGERY, vol.72, no.2, pp.623-625, 2001 (Journal Indexed in SCI) identifier identifier identifier

2000

2000

Serum erythropoietin level in anemic cancer patients

Ozguroglu M. , Arun B., Demir G., Demirelli F. H. , Mandell N., Buyukunal E. , et al.

MEDICAL ONCOLOGY, vol.17, no.1, pp.29-34, 2000 (Journal Indexed in SCI) Sustainable Development identifier identifier identifier

1999

1999

Usefulness of the epithelial tumor marker CA-125 in non-Hodgkin's lymphoma

Ozguroglu M. , Turna H. , Demir G., Doventas A. , Demirelli F. H. , Mandel N. K. , et al.

American Journal of Clinical Oncology: Cancer Clinical Trials, vol.22, no.6, pp.615-618, 1999 (Journal Indexed in SCI Expanded) Sustainable Development identifier identifier identifier

1999

1999

Paraneoplastic hyperpigmentation secondary to lung cancer resolving after chemotherapy

Ozguroglu M. , Tahan V., Ozguroglu E., Ozaras R., Demir G.

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, vol.22, no.5, pp.533-534, 1999 (Journal Indexed in SCI) Sustainable Development identifier identifier identifier

1999

1999

Serum erythropoietin level in anemic cancer patients

Ozguroglu M. , Demir G., Demirelli F., Molinas-Mandel N., Buyukunal E., Serdengecti S., et al.

EUROPEAN JOURNAL OF CANCER, vol.35, 1999 (Journal Indexed in SCI) Sustainable Development identifier

1999

1999

Chemoimmunotherapy protocol for advanced gastric cancer

Demir G., Ozguroglu M. , Molinas-Mandel N., Relli F., Buyukunal E., Serdengecti S., et al.

EUROPEAN JOURNAL OF CANCER, vol.35, 1999 (Journal Indexed in SCI) identifier

1999

1999

Anorectal melanoma metastatic to the breast

Ozguroglu M. , Ozaras R., Tahan V., Demirkesen C., Demir G., Dogusoy G., et al.

JOURNAL OF CLINICAL GASTROENTEROLOGY, vol.29, no.2, pp.197-199, 1999 (Journal Indexed in SCI) identifier identifier identifier

1999

1999

Role of mammographic screening in ovarian cancer

Ozguroglu M. , Esen G., Yildirim B., Demir G., Turna H. , Demirelli F., et al.

EUROPEAN JOURNAL OF CANCER, vol.35, 1999 (Journal Indexed in SCI) Sustainable Development identifier

1999

1999

Bilateral inflammatory breast metastases of epithelial ovarian cancer

Ozguroglu M. , Ersavasti G., Ilvan S. , Hatemi G. , Demir G., Demirelli F. H.

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, vol.22, no.4, pp.408-410, 1999 (Journal Indexed in SCI) Sustainable Development identifier identifier identifier

1999

1999

Serum cardiolipin antibodies in cancer patients with thromboembolic events

Ozduroglu M. , Arun B., Erzin Y., Demir G., Demirelli F., Mandel N., et al.

CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, vol.5, no.3, pp.181-184, 1999 (Journal Indexed in SCI) Creative Commons License identifier identifier identifier

1999

1999

Anaphylaxis from intraperitoneal infusion of cisplatin - A case report

Ozguroglu M. , Demir G., Demirelli F. H. , Mandel N. K.

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, vol.22, no.2, pp.172-173, 1999 (Journal Indexed in SCI) identifier identifier identifier

1999

1999

Microangiopathic hemolytic anemia as an early predictor of recurrence in gastric cancer

Ozguroglu M. , Demirelli F. H. , Mandel N. K.

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, vol.22, no.2, pp.214, 1999 (Journal Indexed in SCI) identifier identifier identifier

1999

1999

Magnetic resonance imaging of bone marrow versus bone marrow biopsy in malignant lymphoma

Özgüroglu M. , Ersavasti G. E. , Demir G., Aki H., Demirelli F., Kanberoglu K., et al.

Pathology and Oncology Research, vol.5, no.2, pp.123-128, 1999 (Journal Indexed in SCI Expanded) identifier identifier

1999

1999

Self expanding metal stents for palliation of dysphagia due to esophageal malignancies

Dobrucali A., Ozguroglu M. , Demir G., Karahasanoglu T., Uzunismail H., Cebeci H., et al.

Turkish Journal of Gastroenterology, vol.10, no.1, pp.18-23, 1999 (Journal Indexed in SCI Expanded) identifier

1998

1998

Immune effects of low-dose subcutaneous interleukin-2 in patients with metastatic malignant melanoma

Demir G., Demirelli F., Ozguroglu M. , Molinas-Mandel N., Buyukunal E., Tuzuner N., et al.

INTERNATIONAL JOURNAL OF IMMUNOTHERAPY, vol.14, no.3, pp.163-168, 1998 (Journal Indexed in SCI) identifier identifier

1997

1997

Generalized telangiectasia as the major manifestation of angiotropic (intravascular) lymphoma

Ozguroglu E., Buyulbabani N., Ozguroglu M. , Baykal C.

BRITISH JOURNAL OF DERMATOLOGY, vol.137, no.3, pp.422-425, 1997 (Journal Indexed in SCI) identifier identifier identifier

1997

1997

Magnetic resonance imaging of bone marrow versus biopsy in malignant lymphoma

Ozguroglu M. , Ersavasti G., Demir G., Demirelli F., Tuzuner N., Kanberoglu K., et al.

EUROPEAN JOURNAL OF CANCER, vol.33, pp.1220, 1997 (Journal Indexed in SCI) identifier

1993

1993

NORADRENERGIC AND SEROTONINERGIC DEPRESSION

YAZICI O., ARICIOGLU F., GURVIT G., UCOK A., TASTABAN Y., CANBERK O., et al.

JOURNAL OF AFFECTIVE DISORDERS, vol.27, no.2, pp.123-129, 1993 (Journal Indexed in SCI) identifier identifier identifier

1991

1991

Spontaneous improvement of tardive dystonia during mania

Yazici O., Kantemir E., Tastaban Y., Ucok A., Ozguroglu M.

British Journal of Psychiatry, vol.158, pp.847-850, 1991 (Journal Indexed in SSCI) identifier identifier identifier

Articles Published in Other Journals

2010

2010

The treatment results of postoperative chemoradiotherapy in gastric carcinoma: Cerrahpasa experience

Oksuz D. C. , Eren M. F. , Bese N. S. , Buyukunal E., Ozguroglu M. , Mandel N. M. , et al.

TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY, vol.25, no.1, pp.1-10, 2010 (Journal Indexed in ESCI) identifier identifier

2006

2006

Skeletal muscle: An unusual site of distant metastasis in gastric carcinoma

Beşe N. Ş. , Özgüroĝlu M. , Dervişoĝlu S., Kanberoǧlu K., Öber A.

Radiation Medicine - Medical Imaging and Radiation Oncology, vol.24, no.2, pp.150-153, 2006 (Refereed Journals of Other Institutions) identifier identifier

2003

2003

Pentoxifylline in the Treatment of Radiation-related Pelvic Insufficiency Fractures of Bone

Beşe N. Ş. , Özgüroǧlu M. , Kamberoǧlu K., Karahasanoglu T., Öber A.

Radiation Medicine - Medical Imaging and Radiation Oncology, vol.21, no.5, pp.223-227, 2003 (Refereed Journals of Other Institutions) identifier identifier

1998

1998

Kadınlarda primeri bilinmeyen aksiller karsinom metastazına yaklaşım: iki olgu bildirimi

ÖZGÜROĞLU M. , Tahan V., ÖZARAS R., Demir G., Çerçel A. , Demirelli F. H. , et al.

Meme Hastalıkları Dergisi, vol.5, pp.172-175, 1998 (Other Refereed National Journals)

Refereed Congress / Symposium Publications in Proceedings

2020

2020

Pembrolizumab (pembro) in microsatellite instability-high (MSI-H) advanced gastric/gastroesophageal junction (G/GEJ) cancer by line of therapy

Chao J., Fuchs C. S. , Shitara K., Tabernero J., Muro K., Van Cutsem E., et al.

Gastrointestinal Cancers Symposium of the American-Society-of-Clinical-Oncology, San-Francisco, Costa Rica, 23 - 25 January 2020, vol.38 Sustainable Development identifier

2020

2020

Time to second progression (PFS2) in patients (pts) from TITAN with metastatic castration-sensitive prostate cancer (mCSPC) by first subsequent therapy (hormonal vs. taxane)

Agarwal N., Chowdhury S., Bjartell A., Chung B. H. , Gomes A. J. P. d. S. , Given R. W. , et al.

Genitourinary Cancers Symposium of the American-Society-of-Clinical-Oncology (ASCO), San-Francisco, Costa Rica, 13 - 15 February 2020, vol.38 Sustainable Development identifier

2020

2020

Apalutamide (APA) for metastatic castration-sensitive prostate cancer (mCSPC) in TITAN: Outcomes in patients (pts) with low- and high-risk disease

Ozguroglu M. , Chowdhury S., Bjartell A., Uemura H., Chung B. H. , Agarwal N., et al.

Genitourinary Cancers Symposium of the American-Society-of-Clinical-Oncology (ASCO), San-Francisco, Costa Rica, 13 - 15 February 2020, vol.38 identifier

2019

2019

Immune-related adverse events associated with immune-checkpoint inhibitors: A single center experience

Samanci N. , Oruc K., Bedir S., Celik E. , Degerli E., Derin S., et al.

Immuno-Oncology Congress of the European-Society-for-Medical-Oncology (ESMO), Geneva, Switzerland, 11 - 14 December 2019, vol.30 identifier

2019

2019

First-line durvalumab plus platinum-etoposide in extensive-stage (ES)-SCLC: Safety, pharmacokinetics (PK) and immunogenicity in CASPIAN

Ozguroglu M. , Goldman J. W. , Reinmuth N., Chen Y., Dvorkin M., Trukhin D., et al.

Immuno-Oncology Congress of the European-Society-for-Medical-Oncology (ESMO), Geneva, Switzerland, 11 - 14 December 2019, vol.30, pp.66 identifier

2019

2019

Overall survival with first-line durvalumab plus platinum-etoposide in patients with extensive-stage (ES)-SCLC in CASPIAN: Subgroup findings from Asia

Nishio M., Ji J. H. , Hotta K., Chiu C., Lee J., Azuma K., et al.

European-Society-for-Medical-Oncology (ESMO) Asia Congress, Singapore, Singapore, 22 - 24 November 2019, vol.30 identifier

2019

2019

Three-year overall survival update from the PACIFIC trial

Wu Y., Gray J. E. , Villegas A., Daniel D. B. , Vicente D., Murakami S., et al.

European-Society-for-Medical-Oncology (ESMO) Asia Congress, Singapore, Singapore, 22 - 24 November 2019, vol.30 identifier

2019

2019

PD-L1 expression, patterns of progression and patient-reported outcomes (PROs) with durvalumab plus platinum-etoposide in ES-SCLC: Results from CASPIAN

Paz-Ares L., Goldman J. W. , Garassino M. C. , Dvorkin M., Trukhin D., Statsenko G., et al.

44th Congress of the European-Society-for-Medical-Oncology (ESMO), Barcelona, Spain, 27 September - 01 October 2019, vol.30, pp.928-929 identifier

2019

2019

Efficacy of durvalumab in patients with stage III NSCLC who experience pneumonitis (PACIFIC)

Vansteenkiste J. F. , Naidoo J., Faivre-Finn C., Ozguroglu M. , Villegas A., Daniel D., et al.

44th Congress of the European-Society-for-Medical-Oncology (ESMO), Barcelona, Spain, 27 September - 01 October 2019, vol.30, pp.592-593 identifier

2019

2019

A challenging task - Identifying carcinoma of unknown primary (CUP) patients according to ESMO guidelines: The CUPISCO trial experience

Pauli C., Bochtler T., Mileshkin L., Baciarello G., Losa F., Ross J., et al.

44th Congress of the European-Society-for-Medical-Oncology (ESMO), Barcelona, Spain, 27 September - 01 October 2019, vol.30 identifier

2019

2019

Trifluridine/tipiracil (FTD/TPI) in patients (pts) aged >= 65 years with metastatic gastric/gastroesophageal junction cancer (mGC/mGEJC): Subgroup analysis from TAGS.

Shitara K., Doi T., Hosaka H., Thuss-Patience P. C. , Santoro A., Jimenez-Fonseca P., et al.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31 May - 04 June 2019, vol.37 Sustainable Development identifier

2019

2019

Three-year overall survival update from the PACIFIC trial.

Gray J. E. , Villegas A. E. , Daniel D. B. , Vicente D., Murakami S., Hui R., et al.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31 May - 04 June 2019, vol.37 identifier

2019

2019

First subsequent treatment after discontinuation of durvalumab in unresectable, stage III NSCLC patients from PACIFIC.

Planchard D., Cho B. C. , Gray J. E. , Paz-Ares L. G. , Ozguroglu M. , Villegas A. E. , et al.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31 May - 04 June 2019, vol.37 identifier

2018

2018

PACIFIC: Overall Survival with Durvalumab versus Placebo after Chemoradiotherapy in Stage III NSCLC

Raben D., Faivre-Finn C., Spigel D., Daniel D., Villegas A., Vincente D., et al.

60th Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO), San-Antonio, Northern Mariana Islands, 21 - 24 October 2018, vol.102, pp.1607-1608 identifier

2017

2017

PACIFIC: A Double-Blind, Placebo-Controlled Phase 3 Study of Durvalumab as Consolidation Therapy After Chemoradiation in Patients with Locally Advanced, Unresectable Non-Small Cell Lung Cancer

Antonia S. J. , Villegas A., Daniel D., Baz D. V. , Murakami S., Hui R., et al.

59th Annual Meeting of the American-Society-for-Therapeutic-Radiation-Oncology (ASTRO), California, United States Of America, 24 - 27 September 2017, vol.99, pp.1314-1315 Sustainable Development identifier

2017

2017

LATITUDE: A phase III, double-blind, randomized trial of androgen deprivation therapy with abiraterone acetate plus prednisone or placebos in newly diagnosed high-risk metastatic hormone-naive prostate cancer

Fizazi K., Tran N., Fein L. E. , Matsubara N., Antolin A. R. , Alekseev B. Y. , et al.

53rd Annual Clinical Science Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Symposium on Old Targets, New Drugs - Her2 and MET, Illinois, United States Of America, 2 - 07 June 2017, vol.35 identifier

2017

2017

Everolimus (EVE) plus endocrine therapy in patients with estrogen receptor-positive (ER plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (BC): First-and second-line data from the BOLERO-4 study.

Cardoso F., Villanueva C., Royce M., Cruz F., Debled M., Hegg R., et al.

53rd Annual Clinical Science Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Symposium on Old Targets, New Drugs - Her2 and MET, Illinois, United States Of America, 2 - 07 June 2017, vol.35 Sustainable Development identifier

2016

2016

Stomatitis in patients treated with first-line everolimus (EVE) plus letrozole (LET): Results from BOLERO-4 trial

Villanueva C., Tsugawa K., Toyama T., Noh W., Jeong J., Cardoso F., et al.

San Antonio Breast Cancer Symposium, San-Antonio, Northern Mariana Islands, 6 - 10 December 2016, vol.77 identifier

2015

2015

Everolimus plus trastuzumab and vinorelbine for trastuzumabresistant, taxane-pretreated, HER2+advanced breast cancer: Overall survival results from BOLERO-3

Isaacs C., O'Regan R., Xu B., Masuda N., Arena F., Yap Y., et al.

38th Annual CTRC-AACR San Antonio Breast Cancer Symposium, San-Antonio, Northern Mariana Islands, 8 - 12 December 2015, vol.76 Sustainable Development identifier

2015

2015

Response to cabazitaxel in patients with metastatic castration-resistant prostate cancer (mCRPC) poorly responding to docetaxel

Angelergues A., Bellmunt J., Efstathiou E., Gonzalez I., Gyftaki R., Delanoy N., et al.

European Cancer Congress / 18th Meeting of the European-Cancer-Organization (ECCO) / 40th Meeting of the European-Society-for-Medical-Oncology (ESMO), Vienna, Austria, 25 - 29 September 2015, vol.51 Sustainable Development identifier

2015

2015

Clinical experience with Vemurafenib in pretreated melanoma (MEL): The results of open label multi center study from Turkey

Celik I., Mandel N. M. , Gokmen E., Unal O. U. , Sevinc A., Coskun H. S. , et al.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, United States Of America, 29 May - 02 June 2015, vol.33 identifier

2013

2013

ER/PR/HER2 receptor discordance between primary tumors and corresponding axillary metastases in curatively resected node positive breast cancer patients

Ozturk M., Turna H. , Aydin O. , Tural D., Demirelli F., Ozguroglu M. , et al.

European Cancer Congress 2013 - 17th ECCO / 38th ESMO / 32nd ESTRO, Amsterdam, Netherlands, 27 September - 01 October 2013, vol.49 Sustainable Development identifier

2013

2013

Clinical significance of p95HER2 Overexpression, PTEN loss and PI3K expression in p185HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies

Tural D., Demirelli F., Serdengecti S., ÖZTÜRK T., Ilvan S., Turna H., et al.

European Cancer Congress 2013 - 17th ECCO / 38th ESMO / 32nd ESTRO, Amsterdam, Netherlands, 27 September - 01 October 2013, vol.49 Sustainable Development identifier

2013

2013

Prognostic factors of survival in patients with metastatic castration resistant prostate cancer (mCRPC) treated with cabazitaxel: Sequencing might matter

Angelergues A., Maillet D., Flechon A., Ozguroglu M. , Mercier F., Guillot A., et al.

49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31 May - 04 June 2013, vol.31 identifier

2012

2012

IMPACT OF CABAZITAXEL (CBZ) plus PREDNISONE (P; CBZP) ON OVERALL SURVIVAL (OS) AT 2 YRS AND IN PATIENTS (PTS) WITH AGGRESSIVE DISEASE: POST-HOC ANALYSES OF TROPIC TRIAL

Oudard S., de Bono J. S. , Ozguroglu M. , Hansen S., Machiels J., Kocak I., et al.

37th Congress of the European-Society-for-Medical-Oncology (ESMO), Vienna, Austria, 28 September - 02 October 2012, vol.23, pp.307-308 identifier

2012

2012

Thromboembolic complications in cancer patients.

Yenidunya G., Turna H. , Ozturk M. A. , Tural D. , Selcukbiricik F., Yildiz O. , et al.

48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 1 - 06 June 2012, vol.30 Sustainable Development identifier

2012

2012

A cohort compassionate-use program with cabazitaxel plus prednisone for patients with metastatic castration-resistant prostate cancer: Interim results.

Bavbek S. E. , Malik Z. I. , Di Lorenzo G., Scholz H., van Oort I. M. , Siobhan Ng S. N. , et al.

48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 1 - 06 June 2012, vol.30 Sustainable Development identifier

2011

2011

Preoperative Chemoradiotherapy Improves Local Recurrence Free Survival in Locally Advanced Rectal Cancer

Turhal D., Ozturk M. A. , Yildiz O., Selcukbiricik F., Elicin O., Erguney S., et al.

European Multidisciplinary Cancer Congress on Integrating Basic and Translational Science, Surgery, Radiotherapy, Medical oncology, Advocacy and Care, Stockholm, Sweden, 23 - 27 September 2011, vol.47 identifier

2011

2011

Tumour Characteristics Determining Response to Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer

Turna Z. S. , Ozturk M. A. , Tural D., Biricik F. S. , Yildiz O., Ozguroglu M. , et al.

European Multidisciplinary Cancer Congress on Integrating Basic and Translational Science, Surgery, Radiotherapy, Medical oncology, Advocacy and Care, Stockholm, Sweden, 23 - 27 September 2011, vol.47 Sustainable Development identifier

2011

2011

KRas and Braf: Is a Predictor in Metastatic Colorectal Cancer Patients for Bevacizumab?

Selcukbiricik F., Yildiz O., Tural D., Ozturk M. A. , Demir G., Ozguroglu M. , et al.

European Multidisciplinary Cancer Congress on Integrating Basic and Translational Science, Surgery, Radiotherapy, Medical oncology, Advocacy and Care, Stockholm, Sweden, 23 - 27 September 2011, vol.47 Sustainable Development identifier

2011

2011

Cabazitaxel Plus Prednisone for Patients With Metastatic Castration-resistant Prostate Cancer Previously Treated With a Docetaxel-containing Regimen - Interim Analysis Results From an Ongoing Compassionate-use Programme

Heidenreich A., Scholz H. J. , van Oort I., Bavbek S., Mueller S., Ozguroglu M. , et al.

European Multidisciplinary Cancer Congress on Integrating Basic and Translational Science, Surgery, Radiotherapy, Medical oncology, Advocacy and Care, Stockholm, Sweden, 23 - 27 September 2011, vol.47 Sustainable Development identifier

2010

2010

INCREASING ROLE OF METASTASECTOMY IN METASTATIC BREAST CANCER PATIENTS: WHO BENEFITS MORE

Selcukbiricik F., Ozguroglu M. , Öztürk M. S. , Turna H. , Tural D., Yildiz O., et al.

35th European-Society-for-Medical-Oncology (ESMO) Congress, Milan, Italy, 8 - 12 October 2010, vol.21, pp.111 Sustainable Development identifier

2010

2010

THE EFFECTS OF PATIENT AND TUMOR CHARECTERISTICS AND TREATMENT MODALITIES ON PROGNOSIS OF PATIENTS WITH UVEAL MELANOMA

Tural D., Ozguroglu M. , Turna H. , Selcukbiricik F., Ozturk M. A. , Sevinc M., et al.

35th European-Society-for-Medical-Oncology (ESMO) Congress, Milan, Italy, 8 - 12 October 2010, vol.21, pp.406 identifier

2009

2009

Is there any future of prophylactic cranial irradiation in adenocarcinoma of the lung?

Ozguroglu M. , Turna H. , Sevinc M., Karaaslan S., Gursu U. R.

15th Congress of the European-Cancer-Organization/34th Multidisciplinary Congress of the European-Society-for-Medical-Oncology, Berlin, Germany, 20 - 24 September 2009, vol.7, pp.534 identifier

2009

2009

The effects of prognostic factors on the first recurrence patterns of breast cancer

Turna H. , Ozguroglu M. , Demir G., Mandel N., Ilvan S., Calay Z., et al.

15th Congress of the European-Cancer-Organization/34th Multidisciplinary Congress of the European-Society-for-Medical-Oncology, Berlin, Germany, 20 - 24 September 2009, vol.7, pp.312 Sustainable Development identifier

2008

2008

AWARENESS OF CANCER DIAGNOSIS IN TURKISH CANCER PATIENTS AND ATTITUDES OF PHYSICIANS AND NURSES TOWARDS DISCLOSURE OF THE DIAGNOSIS

Sayilir A., Ozguroglu M. , Turna H.

33rd European-Society-for-Medical-Oncology Congress, Stockholm, Sweden, 12 - 16 September 2008, vol.19, pp.263 Sustainable Development identifier

2008

2008

CHARACTERISTICS OF THROMBOEMBOLIC COMPLICATIONS IN CANCER PATIENTS

Turna H. , Ozguroglu M. , Guersu R. U. , Karaaslan S., Yildiz O., Yanmaz M. T.

33rd European-Society-for-Medical-Oncology Congress, Stockholm, Sweden, 12 - 16 September 2008, vol.19, pp.256-257 Sustainable Development identifier

2006

2006

Trastuzumab beyond progression in metastatic breast cancer

Yanmaz M. T. , Ozguroglu M. , Ozturk B., Uygun K., Basaran G., Turna H. , et al.

31st Congress of the European-Society-for-Medical-Oncology, İstanbul, Turkey, 29 September - 03 October 2006, vol.17, pp.77 Sustainable Development identifier

2006

2006

Imatinib mesylate response in Gastrointestinal Stromal Tumors: Experience of cerrahpasa medical faculty

Yildiz I., Mandel N. M. , Demir G., Ozguroglu M. , Toptas T. , Buyukunal E. , et al.

31st Congress of the European-Society-for-Medical-Oncology, İstanbul, Turkey, 29 September - 03 October 2006, vol.17, pp.164 identifier

2006

2006

Phase II trial of a combination of weekly docetaxel and four-weekly carboplatin in the first-line treatment of advanced non-small cell lung cancer (NSCLC)

Ozguroglu M. , Evrensel T., Er O., Turna H. , Yanmaz T., Yildiz O. , et al.

31st Congress of the European-Society-for-Medical-Oncology, İstanbul, Turkey, 29 September - 03 October 2006, vol.17, pp.225 Sustainable Development identifier

2004

2004

The evaluation of toxicity and survival results of a phase II trial investigating the role of postoperative chemoradioimmunotherapy for gastric adenocarcinoma

Bese N., Yildirim A., Ober A., Ozguroglu M. , Mandel N., Demir G., et al.

23rd Annual Meeting of the European-Society-for-Therapeutic-Radiology-and-Oncology (ESTRO 23), Amsterdam, Netherlands, 24 - 28 October 2004, vol.73 identifier

2004

2004

Gastric cancer in Turkey: A single center experience of 683 cases

Demir G., Buyukunal E., Kizilkilic E., Ozguroglu M. , Mandel N., Demirelli F., et al.

40th Annual Meeting of the American-Society-of-Clinical-Oncology, Louisiana, United States Of America, 5 - 08 June 2004, vol.22 Sustainable Development identifier

2004

2004

Is the incidence of anal canal cancers different in Moslem societies?

Cabuk D., Yumuk P., Abacioglu U., Demir G., Dane F., Gumus M., et al.

40th Annual Meeting of the American-Society-of-Clinical-Oncology, Louisiana, United States Of America, 5 - 08 June 2004, vol.22 Sustainable Development identifier

2004

2004

The acute phase proteins in cancer patients

Bolayirli I., Ozguroglu M. , Balci H., Orhanoglu T., Hacibekiroglu M.

56th Annual Meeting of the American-Association-for-Clinical-Chemistry, Los-Angeles, Chile, 25 - 29 July 2004, vol.50 Sustainable Development identifier

1999

1999

Significance of serum beta-2 microglobulin in epithelial ovarian cancer

ÖZGÜROĞLU M. , Tahan V., Demir G., ÖZARAS R., Demirelli F. H. , Mandel N. M. , et al.

35th Annual Meeting , American Society of Clinical Oncology., Atlanta, United States Of America, 15 - 18 May 1999, vol.1, pp.382 Sustainable Development

1998

1998

Chemoimmunotherapy protocol in patients with advanced gastric cancer

Demir G., Ozguroglu M. , Belentepe S., Demirelli F., Mandel N., Buyukunal E., et al.

2nd Congress of the Balkan-Union-of-Oncology, İzmir, Turkey, 10 - 14 September 1998, pp.407-411 Sustainable Development identifier

1996

1996

THE ROLE OF LOCAL RADIATION THERAPY IN NEOADJUVANT PROTOCOL OF OSTEOSARCOMA

Uzel M., HIZ V. M. M. , AYDINGÖZ Ö. , Okkan S. , KOCA S. S. , Molinas N., et al.

2ND OSTEOSARCOMA RESEARCH CONFERENCE ABSTRACT BOOK, Italy, 1 - 04 November 1996, pp.21

Activities in Scientific Journals

2021 - Continues

2021 - Continues

LIFE RESEARCH

Evaluation Committee Member

Memberships / Tasks in Scientific Organizations

2017 - Continues

2017 - Continues

FACULTY MEMBER of genitourinary cancers in ESMOSustainable Development

Member of Advisory Board

2013 - Continues

2013 - Continues

BOLERO 4 ÇALIŞMASINDA STEERING COMMITTE ÜYELİĞİ

Board Member

2012 - Continues

2012 - Continues

PROXIMA ÇALIŞMASINDA STEERING COMMITTEE ÜYELİĞİ

Board Member

2021 - 2021

2021 - 2021

ESMO 2021

Member of Science Committee

Scientific Consultations

2020 - Continues

2020 - Continues

Scientific Consultancy

MSD

Istanbul University, Cerrahpasa Faculty Of Medicine, Dahili Bilimler, Turkey

2020 - Continues

2020 - Continues

Scientific Consultancy

MSD

Istanbul University, Cerrahpasa Faculty Of Medicine, Dahili Bilimler, Turkey

2018 - Continues

2018 - Continues

Scientific Consultancy

JANSSEN

Istanbul University, Cerrahpasa Faculty Of Medicine, Dahili Bilimler, Turkey

2013 - Continues

2013 - Continues

Project Consultancy

MEME KANSERİ ÇALIŞMASI

Istanbul University, Cerrahpaşa Tıp Fakültesi, Dahili Bilimler, Turkey

2012 - Continues

2012 - Continues

Project Consultancy

PROSTAT KANSERİ ÇALIŞMASI

Istanbul University, Cerrahpaşa Tıp Fakültesi, Dahili Bilimler, Turkey

2020 - 2023

2020 - 2023

Scientific Consultancy

BAYER

Istanbul University, Cerrahpasa Faculty Of Medicine, Dahili Bilimler, Turkey

Tasks In Event Organizations

Eylül 2021

Eylül 2021

ESMO

Scientific Congress

Özgüroğlu M.
Paris, France

Awards

October 2004

October 2004

best poster in ESMO meeting -pain in cancer patientsSustainable Development

ESMO

July 1999

July 1999

1999 yılındaki SCI ve SCIE kapsamındaki dergilerde uluslararası yayın sıralamasında birincilik ödülü

istanbul üniversitesi



Edit Congress and Symposium Activities

2019

2019

ESMO-IO

Invited Speaker

Geneve-Switzerland

Citations

Total Citations (WOS): 10490

h-index (WOS): 29